As previously reported , raloxifene reduced the incidence of invasive breast cancer by 44 % ( hazard ratio [ HR ] = 0.56 ; 95 % confidence interval [ CI ] = 0.38 to 0.83 ; absolute risk reduction = 1.2 invasive breast cancers per 1000 women treated for 1 year ) .
